Table 1.
Comparison of the baseline characteristics of the patients in the tirofiban and non-tirofiban groups
| Non-tirofiban group (n = 59) | Tirofiban group (n = 59) | P value | |
|---|---|---|---|
| Age, median (IQR) | 63 (55–75) | 71 (61–78) | 0.015 |
| Female | 16 (27.1%) | 23 (39.0%) | 0.171 |
| Prestroke mRS, median (IQR) | 0 (0–0) | 0 (0–0) | 0.438 |
| Initial NIHSS, median (IQR) | 15 (12–21) | 14 (10–20) | 0.322 |
| ASPECTS, median (IQR) | 8 (4.5–9.5) (n = 41) | 8 (6–9) (n = 46) | 0.530 |
| Intravenous rtPA | 29 (49.2%) | 30 (33.9%) | 0.093 |
| Target occlusion location | 0.766 | ||
| Terminal ICA | 9 (15.3%) | 8 (13.6%) | |
| MCA M1 | 34 (57.6%) | 38 (64.4%) | |
| MCA M2 | 2 (3.4%) | 3 (5.1%) | |
| VBA | 14 (23.7%) | 10 (16.9%) | |
| Hypertension | 38 (64.4%) | 38 (64.4%) | > 0.999 |
| Diabetes mellitus | 19 (32.2%) | 18 (30.5%) | 0.843 |
| Dyslipidemia | 25 (42.4%) | 14 (23.7%) | 0.031 |
| Atrial fibrillation | 12 (20.3%) | 9 (15.3%) | 0.470 |
| Coronary disease | 3 (5.1%) | 4 (6.8%) | > 0.999a |
| Smoking | 21 (35.6%) | 23 (39.0%) | 0.703 |
| Prior antiplatelet | 6 (10.2%) | 13 (22.0%) | 0.080 |
| Prior anticoagulant | 4 (6.8%) | 1 (1.7%) | 0.364a |
ASPECTS Alberta Stroke Program Early CT Score, ICA internal carotid artery, IQR interquartile range, MCA middle cerebral artery, mRS modified Rankin Scale, NIHSS National Institute of Health Stroke Scale, rtPA recombinant tissue plasminogen activator, VBA vertebro-basilar artery
aFisher’s exact t-test